Tactile Systems beats Q4 estimates with 46¢ EPS and buys LymphaTech for $6.8M
Tactile Systems reported Q4 net income of $10.6 million, delivering 46¢ EPS and $103.6 million revenue, exceeding analyst estimates of 44¢ and $93.7 million. The company also agreed to acquire LymphaTech for $6.8 million upfront plus milestone payments, adding a 3D digital lymphedema measurement platform.
1. Q4 Earnings Beat Estimates
Tactile Systems posted net income of $10.6 million, or 46 cents per share, on revenue of $103.6 million in the fourth quarter, surpassing consensus forecasts of 44 cents EPS and $93.7 million revenue.
2. Full-Year Profit and 2026 Guidance
For the full year, the company earned $19.1 million, or 82 cents per share, on revenue of $329.5 million, and projects 2026 revenue between $357 million and $365 million.
3. Acquisition of LymphaTech
Tactile Systems agreed to acquire LymphaTech for an upfront cash payment of $6.8 million and additional milestone-based consideration, integrating LymphaTech’s clinically validated 3D full-body measurement and monitoring platform.
4. Strategic Expansion of Lymphedema Solutions
The acquisition expands Tactile’s lymphedema portfolio with advanced digital measurement, supports longitudinal patient surveillance, enhances research capabilities and bolsters the company’s leadership in lymphatic dysfunction therapies.